

091-21232fn

For Internal Use Only RECEIVED	Submit 1 Original	OMB Approval No.:
Sec File No. 91 -	and 9 Copies	Expires:
2016 AUG 30 PM 1:21		Estimated average burden hours per response: 2.00

**UNITED STATES
SEC / TM SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product: **NYSE Arca, Inc. (trading pursuant to unlisted trading privileges)** **SEC
Mail Processing**

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.): **Open-end Management Investment Company** **Section
AUG 30 2016**

3. Class of New Derivative Securities Product: **Investment Company Units** **Washington DC
412**

4. Name of Underlying Instrument: **Nasdaq Healthcare Innovators Index**

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based: **Narrow-Based**

6. Ticker Symbol(s) of New Derivative Securities Product: **BTEC**

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades: **NYSE, NASDAQ, NYSE MKT**

8. Settlement Methodology of New Derivative Securities Product: **Regular way trades settle on T+3/Book entry only held in DTC.**



9. Position Limits of New Derivative Securities Product (if applicable): **Not applicable.** **16019143**

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: **Martha Redding**

Title: **Associate General Counsel and Assistant Secretary**

Telephone Number: **(212) 656-2938**

Manual Signature of Official Responsible for Form:

[Handwritten Signature]
August 29, 2016
SEC 2449 (1/99)

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	AUG 30 2016



Martha Redding
Senior Counsel
Assistant Secretary

RECEIVED
2016 AUG 30 PM 1:20
SEC / TM

New York Stock Exchange
11 Wall Street
New York, NY 10005
T + 1 212 656 2938
F + 1 212 656 8101
Martha.Redding@theice.com

Via Overnight Mail

August 29, 2016

Ms. Gail Jackson
US Securities and Exchange Commission
Division of Trading and Markets
Station Place – Building I
100 F Street, N.E. – Room 6628
Washington, DC 20549

SEC
Mail Processing
Section
AUG 30 2016
Washington DC
412

Re: 19b-4(e) – Transmittal

Dear Ms. Jackson:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

- iSectors Post-MPT Growth ETF (PMPT)**
- Principal Healthcare Innovators Index ETF (BTEC)**
- Principal Millennials Index ETF (GENY)**
- Dirxion Daily FTSE Developed Markets Bull 1.25X Shares (LLDM)**
- Dirxion Daily FTSE Europe Bull 3X Shares (EURL)**
- First Trust Horizon Managed Volatility Domestic ETF (HUSV)**
- First Trust Horizon Managed Volatility Developed International ETF (HDMV)**

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,


Enclosures

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	AUG 30 2016